HLB, a global biopharmaceuticals company, said Thursday that its U.S. subsidiary Elevar Therapeutics announced the efficacy and safety of the Rivoceranib liver cancer drug at a biopharmaceutical symposium in Washington, D.C. This comes as part of the Korean biotech company's efforts to promote the drug ahead of applying for new drug application (NDA) with the U.S. Food and Drug Administration. 

Please refer to the following website for further details:   

https://www.koreatimes.co.kr/www/tech/2023/03/779_347685.html